- Home
- Publications
- Publication Search
- Publication Details
Title
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure
Authors
Keywords
-
Journal
CIRCULATION
Volume 142, Issue 12, Pages 1205-1218
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-09-22
DOI
10.1161/circulationaha.120.045888
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
- (2020) Eileen O’Meara et al. CANADIAN JOURNAL OF CARDIOLOGY
- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
- (2020) Abhinav Sharma et al. CIRCULATION
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY
- (2020) Alan J. Garber et al. Endocrine Practice
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Standards of medical care for type 2 diabetes in China‐0027
- (2019) Weiping Jia et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. CIRCULATION
- Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
- (2019) Maurice B. Bizino et al. Cardiovascular Diabetology
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial
- (2019) Marat Fudim et al. CIRCULATION
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity
- (2019) Ali Aminian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America” Journal of Cardiac Failure Vol. 25 No. 8, pp. 584-619
- (2019) SHANNON M. DUNLAY et al. JOURNAL OF CARDIAC FAILURE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017
- (2019) Andrew Sumarsono et al. JAMA Internal Medicine
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction
- (2018) Goh Eun Chung et al. ATHEROSCLEROSIS
- 2018 Clinical Practice Guidelines Committees
- (2018) Canadian Journal of Diabetes
- Leptin-Aldosterone-Neprilysin Axis
- (2018) Milton Packer CIRCULATION
- Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure
- (2018) Abhinav Sharma et al. Circulation-Heart Failure
- The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest
- (2018) Sebastian Wiberg et al. CRITICAL CARE MEDICINE
- Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
- (2018) Sarita Bajaj International Journal of Diabetes in Developing Countries
- NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL
- (2018) Mansoor Husain et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
- (2018) Chengshi Wang et al. PLoS One
- GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction
- (2018) T. Dung Nguyen et al. Journal of Cardiovascular Translational Research
- Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis
- (2018) Karn Wijarnpreecha et al. DIGESTIVE AND LIVER DISEASE
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Effects of intentional weight loss in patients with obesity and heart failure: a systematic review
- (2018) K. McDowell et al. Obesity Reviews
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
- (2018) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2018) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Spencer L James et al. LANCET
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis
- (2018) Tannous K. Fakhry et al. Surgery for Obesity and Related Diseases
- Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
- (2018) Jordan Rowlands et al. Frontiers in Endocrinology
- Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney
- (2017) Dilip K. Deb et al. FASEB JOURNAL
- HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin
- (2017) Ulrika Ljung Faxén et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide causes large and rapid epicardial fat reduction
- (2017) Gianluca Iacobellis et al. Obesity
- Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction
- (2017) Sanjiv J. Shah Journal of Cardiovascular Translational Research
- Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
- (2017) Inka Miñambres et al. Diabetology & Metabolic Syndrome
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
- (2017) Michelle Orme et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs
- (2016) Adam D. DeVore et al. AMERICAN JOURNAL OF CARDIOLOGY
- Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial β-oxidation in cardiomyocytes via activation of the cardiac renin–angiotensin system and induction of miR-208a
- (2016) Marcel Blumensatt et al. BASIC RESEARCH IN CARDIOLOGY
- Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males
- (2016) Mark M. Smits et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry
- (2016) Giovanni Targher et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction
- (2016) Dalane W. Kitzman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
- (2016) Isabelle Johansson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- (2016) Young-Sun Lee et al. MEDIATORS OF INFLAMMATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity
- (2016) R. Burcelin et al. Obesity Reviews
- The effects of bariatric surgeries on nonalcoholic fatty liver disease
- (2016) Tamadar Aldoheyan et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: The Look AHEAD randomized trial
- (2015) Alvaro Alonso et al. AMERICAN HEART JOURNAL
- Concomitant Diabetes Mellitus and Heart Failure
- (2015) Alessandra Dei Cas et al. CURRENT PROBLEMS IN CARDIOLOGY
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials
- (2015) Patrick Rossignol et al. EUROPEAN JOURNAL OF HEART FAILURE
- Successful Weight Reduction Improves Left Ventricular Diastolic Function and Physical Performance in Severe Obesity
- (2015) Sabine Fenk et al. International Heart Journal
- Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease
- (2015) Salvatore Petta et al. JOURNAL OF HEPATOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
- (2015) Jacob A Udell et al. Lancet Diabetes & Endocrinology
- Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
- (2015) Alessandra Dei Cas et al. JACC-Heart Failure
- Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes
- (2015) Alessandro Mantovani et al. PLoS One
- Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
- (2014) Hui Fan et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Direct cardiovascular effects of glucagon like peptide-1
- (2013) Asfandyar Sheikh Diabetology & Metabolic Syndrome
- Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis
- (2013) A. Cignarelli et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Meta-Analysis of the Relation of Echocardiographic Epicardial Adipose Tissue Thickness and the Metabolic Syndrome
- (2012) Sante D. Pierdomenico et al. AMERICAN JOURNAL OF CARDIOLOGY
- High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
- (2012) L. J. M. Boonman-de Winter et al. DIABETOLOGIA
- Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
- (2012) Stuart J. Pocock et al. EUROPEAN HEART JOURNAL
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started